Jill Lacy, MD
Professor of Medicine (Medical Oncology)Cards
Appointments
Contact Info
About
Titles
Professor of Medicine (Medical Oncology)
Biography
Dr. Jill Lacy is Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine with over 30 years of experience as a practicing Medical Oncologist. Dr. Lacy graduated from Yale School of Medicine in 1978, completed training in Internal Medicine and Medical Oncology at Yale, and is board-certified in Internal Medicine and Medical Oncology. Dr. Lacy's early career was focused on clinical and basic research related to Epstein Barr virus-mediated oncogenesis and HIV-associated malignancies during the height of the AIDS epidemic. In recent years, Dr. Lacy's clinical practice has been devoted to caring for patients with gastrointestinal malignancies. Her current research is focused on therapeutic clinical trials in GI malignancies, including gastroesophageal, pancreatic, and colorectal cancers. She is the principle investigator on a number of investigator-initiated, pharmaceutical, and cooperative group studies. She has served on national committees focused on optimizing the education of Medical Oncology trainees and recruiting minority students to careers in Oncology.
Appointments
Medical Oncology
ProfessorPrimary
Other Departments & Organizations
- Cancer-Infectious Diseases (Cancer-ID) Program
- Center for Gastrointestinal Cancers
- Developmental Therapeutics
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Internal Medicine
- Medical Oncology
- Oligometastatic Cancer Program
- Pancreatic Diseases Program
- Sarcoma Program
- Subset Medical Oncology Faculty
- Yale Cancer Center
- Yale Medicine
- Yale Ventures
Education & Training
- Fellow
- Yale University School of Medicine (1985)
- Resident
- Yale University School of Medicine (1982)
- MD
- Yale University (1978)
Research
Overview
Dr. Jill Lacy is a Professor of Medicine in the Section of Medical Oncology at the Yale School of Medicine. She has a large clinical practice in the Gastrointestinal Malignancies Unit at Smilow Cancer Center. After transitioning from lab-based basic research in the field of EBV-associated malignancies, she has been actively engaged in clinical investigation, focusing on therapeutic clinical trials. She has developed and conducted several investigator-initiated trials, and, in addition, has served as the site Principle Investigator on dozens of cooperative group and industry sponsored trials, leading to co-authorship in high impact journals. Her specific research interests include discovery of novel therapeutics for gastroesophageal and pancreatic cancers. In her role as an investigator in the Smilow Cancer Center Disease Aligned Research Team for GI Malignancies, she has been instrumental in developing the clinical trials portfolio and fostering translational research for GI Cancers at Yale. In addition to her involvement in patient care and research, Dr. Lacy served at the Program Director of the Hematology-Medical Oncology Fellowship Program at Yale for over 20 years, playing an active role in mentoring Fellows in their research projects and development. Aligned with this commitment to education, she has been actively involved in ASCO in issues related to trainee education, including service as Editor of the ASCO Self-Evaluation Program.
Research at a Glance
Yale Co-Authors
Publications Timeline
Stacey Stein, MD
Jeremy Kortmansky, MD
Michael Cecchini, MD
Kimberly L. Johung, MD, PhD
David Coleman, MD
Neal Fischbach, MD
Publications
2024
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations
Yasin F, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Zhang J, Ross J, Cecchini M. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. The Oncologist 2024, oyae259. PMID: 39401325, DOI: 10.1093/oncolo/oyae259.Peer-Reviewed Original ResearchCitationsConceptsAdvanced colorectal cancerPIK3CA mutationsColorectal cancerPI3K inhibitionPI3K inhibitorsBurden of colorectal cancerActivating mutationsResponse to PI3K inhibitionSensitive to PI3K inhibition.Foundation Medicine databaseMetastatic colorectal cancerClinically relevant mutationsMicrosatellite instability-highPI3K signalingTumor DNAPIK3CA variantsClinical carePIK3CA oncogeneClinical variablesE545KGenomic profilingPIK3CAE542KMedicine DatabasePatientsDevimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
Philip P, Sahai V, Bahary N, Mahipal A, Kasi A, Lima C, Alistar A, Oberstein P, Golan T, Metges J, Lacy J, Fountzilas C, Lopez C, Ducreux M, Hammel P, Salem M, Bajor D, Benson A, Luther S, Pardee T, Van Cutsem E. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. Journal Of Clinical Oncology 2024, 42: 3692-3701. PMID: 39088774, DOI: 10.1200/jco.23.02659.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMetastatic pancreatic adenocarcinomaOverall survivalCPI-613Randomized phase III trialTreatment-emergent adverse eventsExperimental armDifficult-to-treat diseaseFavorable performance statusProgression-free survivalTreatment naive patientsFirst-line therapyPhase I studyPhase III trialsMedian OSMetastatic adenocarcinomaIII trialsFirst-linePerformance statusPancreatic adenocarcinomaAdverse eventsDevimistatDay 1Disease progressionControl armPatientsA single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original ResearchAltmetricCombining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)
Hochster H, Catalano P, Weitz M, Mitchell E, Cohen D, O’Dwyer P, Faller B, Kortmansky J, O’Hara M, Kricher S, Lacy J, Lenz H, Verma U, Benson A. Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). Journal Of The National Cancer Institute 2024, 116: 1487-1494. PMID: 38775718, PMCID: PMC11378308, DOI: 10.1093/jnci/djae114.Peer-Reviewed Original ResearchCitationsConceptsProgression-free survivalDisease-control ratePhase 3 trialColorectal cancerAnti-VEGFAnti-VEGFRAnti-EGFRKRAS-wild type colorectal cancerPhase II study of irinotecanKRAS wild-type colorectal cancerMedian progression-free survivalRandomized phase II studyKRAS wild-type tumorsWild-type colorectal cancerAnti-VEGFR antibodiesAnti-VEGF drugsTreated with ICSecond-line treatmentStudy of irinotecanWild-type tumorsAdvanced colorectal cancerPhase 2 studyAnti-EGFR antibodiesAnti-VEGF antibodyECOG PS
2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Cecchini M, Cleary J, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky J, Canosa S, Sklar J, Swisher E, Radke M, Ivy P, Boerner S, Durecki D, Hsu C, LoRusso P, Lacy J. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British Journal Of Cancer 2023, 130: 476-482. PMID: 38135713, PMCID: PMC10844282, DOI: 10.1038/s41416-023-02534-1.Peer-Reviewed Original ResearchCitationsAltmetricQuantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsWhole-exome sequencingMGMT protein expressionColorectal cancerStable diseaseQuantitative immunofluorescenceT cellsProtein expressionPromoter hypermethylationLow MGMT protein expressionPARP inhibitorsRadiographic tumor regressionMetastatic colorectal cancerAdvanced colorectal cancerPretreatment tumor biopsiesEffector T cellsTumor-infiltrating lymphocytesMGMT proteinDNA repair biomarkersBaseline CD8Eligible patientsIncreased CD8Methylguanine-DNA methyltransferaseObjective responseProgressive diseaseImmune markersPre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinomaEsophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Ajani J, D'Amico T, Bentrem D, Cooke D, Corvera C, Das P, Enzinger P, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter W, Ilson D, Jalal S, Keswani R, Kim S, Kleinberg L, Klempner S, Lacy J, Licciardi F, Ly Q, Matkowskyj K, McNamara M, Miller A, Mukherjee S, Mulcahy M, Outlaw D, Perry K, Pimiento J, Poultsides G, Reznik S, Roses R, Strong V, Su S, Wang H, Wiesner G, Willett C, Yakoub D, Yoon H, McMillian N, Pluchino L. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 393-422. PMID: 37015332, DOI: 10.6004/jnccn.2023.0019.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEsophagogastric junction cancerSquamous cell carcinomaJunction cancerMetastatic diseaseSystemic therapyNCCN Clinical Practice GuidelinesEsophageal squamous cell carcinomaMajor global health problemBest supportive careManagement of recurrentMultidisciplinary team managementClinical practice guidelinesTreatment of patientsGlobal health problemMicrosatellite instability statusNCCN guidelinesPalliative managementSupportive careEsophagogastric junctionCell carcinomaLower esophagusEsophageal cancerHER2 statusTumor locationBiomarker testingAtezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
Ko A, Kim K, Siveke J, Lopez C, Lacy J, O'Reilly E, Macarulla T, Manji G, Lee J, Ajani J, Alsina Maqueda M, Rha S, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh C, Gan X, Cha E, Oh D. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The Oncologist 2023, 28: 553-e472. PMID: 36940261, PMCID: PMC10243783, DOI: 10.1093/oncolo/oyad022.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsObjective response ratePancreatic ductal adenocarcinomaGrade 3/4 adverse eventsGrade 5 adverse eventsAdverse eventsGastric cancerDuctal adenocarcinomaPhase Ib/II trialAdvanced pancreatic ductal adenocarcinomaLimited clinical activitySafety of atezolizumabRecombinant human hyaluronidaseEligible patientsVersus ChemotherapyII trialPrimary endpointRECIST 1.1Early efficacySafety profileAtezolizumabClinical activitySafety signalsPEGPH20Response rateHuman hyaluronidaseEffect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma
Huffman B, Mallick A, Horick N, Wang-Gillam A, Hosein P, Morse M, Beg M, Murphy J, Mavroukakis S, Zaki A, Schlechter B, Sanoff H, Manz C, Wolpin B, Arlen P, Lacy J, Cleary J. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma. JAMA Network Open 2023, 6: e2249720. PMID: 36602796, PMCID: PMC9856813, DOI: 10.1001/jamanetworkopen.2022.49720.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdvanced pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaObjective response rateProgression-free survivalSecond-line treatmentNab-paclitaxelOverall survivalClinical trialsDuctal adenocarcinomaRandomized phase II clinical trialMedian progression-free survivalGemcitabine/nab-paclitaxelCox proportional hazards analysisEnd pointPhase II clinical trialChemotherapy dose reductionsFirst-line FOLFIRINOXSecond-line gemcitabineMedian overall survivalPrimary end pointSecondary end pointsProportional hazards analysisSurvival of patientsLow performance statusPretreatment clinical variables
Clinical Trials
Current Trials
A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
HIC ID2000033245RolePrincipal InvestigatorPrimary Completion Date09/30/2025Recruiting ParticipantsPhase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
HIC ID2000033374RoleSub InvestigatorPrimary Completion Date07/31/2025Recruiting ParticipantsColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
HIC ID2000032928RoleSub InvestigatorPrimary Completion Date03/10/2029Recruiting ParticipantsRandomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
HIC ID2000032098RoleSub InvestigatorPrimary Completion Date03/31/2025Recruiting ParticipantsA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
HIC ID2000031542RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting Participants
Academic Achievements & Community Involvement
honor Fellow
National AwardAmerican Society of Clinical OncologyDetails05/13/2021United Stateshonor America's Top Doctors (digital guide): 2016, 2017, 2018, 2019, 2020, 2021
National AwardCastle ConnollyDetails05/13/2021United Stateshonor Exceptional Women In Medicine
National AwardCastle ConnollyDetails05/01/2019United Stateshonor Castle Connolly America's Top Doctors for Cancer (digital guide): 2016, 2017, 2018, 2019, 2020, 2021
UnknownDetails09/14/2015United Stateshonor Top Doctors for Cancer, Newsweek Magazine July 2015
National AwardDetails09/14/2015United States
Clinical Care
Overview
Jill Lacy, MD, is a medical oncologist who specializes in gastrointestinal (GI) cancers, including pancreatic and colorectal cancers.
Dr. Lacy works with patients using chemotherapy (which destroys cancer cells with chemicals), immunotherapy (which uses drugs to harness the immune system to fight cancer), and targeted therapy (which targets proteins that control how cancer cells behave).
An active researcher, Dr. Lacy has published studies examining the outcomes of targeted therapy and GI cancers, including potentially harmful side effects, and different treatments for metastatic pancreatic cancer.
In 2020, Dr. Lacy was one of five physicians receiving a Yale Medicine Distinguished Clinical Career Award. The award highlights doctors whose careers demonstrate significant accomplishments and dedication.
Clinical Specialties
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicinePancreatic Cancer
Learn More on Yale MedicineGastrointestinal Stromal Tumors (GIST)
Learn More on Yale MedicineEndocrine Cancer
Learn More on Yale Medicine
Board Certifications
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1982
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- June 20, 2024
Chemotherapy Before Surgery Benefits Some Patients With Pancreatic Cancer
- May 24, 2024
Gastrointestinal Cancer CME Series: Gastroesophageal Cancers
- November 17, 2023
Smilow Shares: Pancreatic Cancer Awareness Day
- November 02, 2023
Offering Specialized Care & Research For Patients with Cancer and HIV
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.